Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HEC585 in Healthy Subjects
NCT03092102Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- May 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of yifenidone in idiopathic pulmonary fibrosis (IPF) (14 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Plasma Concentration at 216 hours, Area Under the Curve from time zero to infinity at 216 hours and 4 more. Started May 2017; status: completed.
02
Drugs
yifenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03092102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092102.